Two Sigma Advisers’s Avidity Biosciences RNAM Stock Holding History

Two Sigma Advisers’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-16,400	Closed	-$477K	–	2550
2024 Q4	$477K	Sell	16,400 -65,500	-80%	-$2.74M	﹤0.01%	1792
2024 Q3	$3.76M	Sell	81,900 -167,500	-67%	-$7.27M	0.01%	809
2024 Q2	$10.2M	Sell	249,400 -204,500	-45%	-$5.87M	0.02%	535
2024 Q1	$11.6M	Sell	453,900 -50,200	-10%	-$787K	0.03%	490
2023 Q4	$4.56M	Sell	504,100 -35,300	-7%	-$236K	0.01%	851
2023 Q3	$3.44M	Buy	539,400 +191,900	+55%	+$1.65M	0.01%	912
2023 Q2	$3.85M	Buy	347,500 +206,300	+146%	+$2.59M	0.01%	877
2023 Q1	$2.17M	Buy	141,200 +84,400	+149%	+$1.86M	0.01%	1236
2022 Q4	$1.26M	Buy	+56,800	New	+$847K	﹤0.01%	1462

Other funds holding RNAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers's RNAM Position: Q1 2025 in Review

Two Sigma Advisers sold out of Avidity Biosciences (RNAM) in Q1 2025, closing a stake of 16,400 shares — an estimated $477K sold.

Two Sigma Advisers first reported a position in RNAM in Q4 2022 and held it in 9 quarters. The position peaked at $11.6M in Q1 2024. 220 funds tracked by Wall St. Rank hold RNAM as of Q1 2025.

Two Sigma Advisers reported no remaining Avidity Biosciences position as of Q1 2025 after selling out during the quarter.
Two Sigma Advisers sold 16,400 Avidity Biosciences shares in Q1 2025, an estimated $477K.
Two Sigma Advisers first reported a position in Avidity Biosciences in Q4 2022 and held it in 9 quarters.
Two Sigma Advisers's Avidity Biosciences position peaked at $11.6M in Q1 2024.
220 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2025.

Based on Two Sigma Advisers's 13F filing for Q1 2025, filed 15 May 2025.